Skip to main content
. 2017 Dec 5;12:3469–3485. doi: 10.2147/COPD.S146338

Figure 1.

Figure 1

PRISMA flow diagram for the identification of studies included in the meta-analysis concerning the impact of LABA/LAMA FDCs on cardiovascular SAEs in COPD patients.

Abbreviations: COPD, chronic obstructive pulmonary disease; FDCs, fixed-dose combinations; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; PK, pharmacokinetic; RCT, randomized controlled trial; SAEs, serious adverse events.